



ORIGINAL ARTICLE

Inotropes and cardiorenal syndrome in acute heart failure – A retrospective comparative analysis



Marta Madeira^{a,b,*}, Francisca Caetano^c, Inês Almeida^a, Andreia Fernandes^a,
Liliana Reis^a, Marco Costa^a, Lino Gonçalves^{a,b}

^a Serviço de Cardiologia, Centro Hospitalar e Universitário de Coimbra – Hospital Geral, Coimbra, Portugal

^b Faculdade de Medicina da Universidade de Coimbra, Coimbra, Portugal

^c King's College Hospital NHS Foundation Trust, Critical Care Department, London, United Kingdom

Received 10 February 2016; accepted 23 March 2017

Available online 18 August 2017

KEYWORDS

Heart failure;
Cardiorenal
syndrome;
Levosimendan;
Dobutamine

Abstract

Introduction: Cardiorenal syndrome (CRS) is common in acute heart failure (AHF), and is associated with dire prognosis. Levosimendan, a positive inotrope that also has diuretic effects, may improve patients' renal profile. Published results are conflicting.

Objectives: We aimed to assess the incidence of CRS in AHF patients according to the inotrope used and to determine its predictors in order to identify patients who could benefit from the most renoprotective inotrope.

Methods: In a retrospective study, 108 consecutive patients with AHF who required inotropes were divided into two groups according to the inotrope used (levosimendan vs. dobutamine). The primary endpoint was CRS incidence. Follow-up for mortality and readmission for AHF was conducted.

Results: Seventy-one percent of the study population were treated with levosimendan and the remainder with dobutamine. No differences were found in heart failure etiology or chronic kidney disease. At admission, the dobutamine group had lower blood pressure; there were no differences in estimated glomerular filtration rate or cystatin C levels. The levosimendan group had lower left ventricular ejection fraction. CRS incidence was higher in the dobutamine group, and they more often had incomplete recovery of renal function at discharge. In multivariate analysis, cystatin C levels predicted CRS. The dobutamine group had higher in-hospital mortality, of which CRS and the inotrope used were predictors.

Conclusions: Levosimendan appears to have some renoprotective effect, as it was associated with a lower incidence of CRS and better recovery of renal function at discharge. Identification of patients at increased risk of renal dysfunction by assessing cystatin C may enable more tailored therapy, minimizing the incidence of CRS and its negative impact on outcome in AHF.

© 2017 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L.U. All rights reserved.

* Corresponding author.

E-mail address: marta.jesus.madeira@gmail.com (M. Madeira).

PALAVRAS-CHAVE

Insuficiência cardíaca;
Síndrome cardiorenal;
Levosimendano;
Dobutamina

Inotrópicos e síndrome cardiorenal na insuficiência cardíaca aguda – análise comparativa retrospectiva**Resumo**

Introdução: A síndrome cardiorenal (SCR) é comum na insuficiência cardíaca aguda (ICA), associando-se a um prognóstico sombrio. O levosimendano, aliando um efeito inotrópico e diurético, poderá ter melhor perfil renal. A literatura é controversa.

Objetivos: Avaliar em doentes com ICA a incidência de SCR em função do inotrópico utilizado. Determinar preditores de SCR, identificando os doentes que possam beneficiar do inotrópico com melhor perfil renoprotetor.

Métodos: Estudo retrospectivo, incluindo 108 doentes consecutivos com ICA tratados com inotrópicos. Criados dois grupos consoante o inotrópico utilizado (levosimendano e dobutamina). O *endpoint* primário foi incidência de SCR. Realizado seguimento relativo a mortalidade e hospitalização por ICA.

Resultados: O levosimendano foi usado em 71% dos doentes e a dobutamina nos restantes. Sem diferenças na etiologia da IC ou incidência de doença renal crónica. À admissão, o grupo-dobutamina apresentava menor pressão arterial sistólica; sem diferenças na taxa de filtração glomerular (TFG) ou cistatina C. O grupo-levosimendano apresentava disfunção ventricular esquerda mais grave. A incidência de SCR foi maior no grupo-dobutamina, com recuperação incompleta da TFG à alta hospitalar. Em análise multivariada, a cistatina C foi preditora de SCR. A mortalidade intra-hospitalar foi superior no grupo-dobutamina, sendo a SCR e o inotrópico utilizados preditores desta.

Conclusões: O levosimendano parece ter melhor perfil renal, associando-se a menor incidência de SCR, com recuperação da função renal. A cistatina C, ao identificar os doentes em maior risco de disfunção renal, poderá permitir uma terapêutica mais individualizada, reduzindo a incidência de SCR e seu impacto negativo no prognóstico da ICA.

© 2017 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L.U. Todos os direitos reservados.

Introduction

Acute heart failure (AHF) remains the single most common admitting diagnosis in industrialized countries, despite significant advances in pharmacologic and device therapy.^{1,2} Some degree of renal impairment is present in more than a third of patients with AHF, associated with reduction in renal blood flow and/or elevation in central venous pressure, leading to a decrease in estimated glomerular filtration rate (eGFR).^{3–5} Conversely, renal impairment itself may predispose to worsening heart failure (HF), through constant salt and water retention, diuretic resistance and neurohormonal activation, leading to increased cardiac workload.^{6,7} In a broad spectrum of patients with chronic HF in the CHARM study,⁸ renal dysfunction was independently associated with increased risk of death, cardiovascular death, and hospitalization due to AHF.⁹ Furthermore, in advanced chronic HF, renal impairment was a stronger predictor of mortality than either left ventricular ejection fraction (LVEF) or New York Heart Association (NYHA) functional class.¹⁰

Both dobutamine and levosimendan are inotropic drugs, used specifically to improve cardiac contractility.¹¹ Through activation of ATP-sensitive potassium channels, levosimendan causes both arterial and venous vasodilation (mainly the latter).¹¹ This additional effect of levosimendan over dobutamine may be crucial in AHF, since central venous pressure is an independent predictor of cardiorenal syndrome (CRS) in this setting.¹²

However, only a few studies comparing the effects of levosimendan with dobutamine on renal function in patients hospitalized with AHF have been published.^{13,14}

We aimed to assess the incidence of CRS according to the inotrope used and to determine its predictors in order to identify patients who could benefit from the most renoprotective inotrope.

The primary endpoint was CRS incidence during hospital stay. The secondary endpoints were recovery of eGFR at discharge, readmission for AHF and mortality during follow-up.

Methods**Population and study design**

We retrospectively studied 108 consecutive patients admitted between May 2009 and March 2014 to a single cardiac intensive care unit for AHF with symptoms or signs of severe congestion or low cardiac output requiring inotropes. The diagnosis of AHF was established according to the current European Society of Cardiology guidelines.¹⁵

Patients with end-stage renal disease on a regular program of renal replacement therapy were excluded.

The sample was divided into two groups according to the inotrope used (levosimendan or dobutamine), prescribed at the discretion of the admitting physician. In the levosimendan group no initial bolus was given and perfusion

was started at 0.1 $\mu\text{g}/\text{kg}/\text{min}$ and titrated up to 0.2 $\mu\text{g}/\text{kg}/\text{min}$ if tolerated. In the dobutamine group perfusion was started at 5.0 $\mu\text{g}/\text{kg}/\text{min}$ and titrated on a clinical basis.

CRS was defined as an increase of ≥ 26.5 $\mu\text{mol}/\text{l}$ in serum creatinine relative to the admission value.¹⁶ The Modification of Diet in Renal Disease (MDRD) equation was used to calculate eGFR, according to the recommendations of the KDIGO Clinical Practice Guideline for Acute Kidney Injury.¹⁷ Changes in renal function were assessed by determining maximum and discharge creatinine and blood urea nitrogen (BUN) and minimum eGFR.

The study is in accordance with the principles outlined in the Declaration of Helsinki.

Data collection

Baseline data were collected from patients' medical records and included previous medical history (time course and etiology of HF, ischemic heart disease, hypertension, diabetes and chronic renal failure and current therapy), physical examination at admission (heart rate and blood pressure), electrocardiogram and blood test analysis (creatinine, BUN, ionogram, N-terminal pro-B-type natriuretic peptide [NT-pro-BNP], hemoglobin, total bilirubin, alkaline phosphatase, aspartate transaminase [AST], alanine transaminase [ALT] and cystatin C).

All patients underwent transthoracic echocardiography with assessment of both systolic (LVEF by the modified Simpson's rule) and diastolic function.

Therapies analyzed were maximum daily dose of furosemide and type of administration (bolus vs. perfusion), use of vasodilator doses of dopamine and noradrenaline, renal support therapy and noninvasive or invasive mechanical ventilation.

In-hospital mortality and length of hospital stay were analyzed.

Readmission for AHF and mortality during follow-up were also obtained from clinical records from outpatient clinic, hospital ward and emergency department admissions and through phone calls for patients not followed at our hospital.

Statistical analysis

The statistical analysis was performed with SPSS version 21.0 (IBM SPSS Inc., Chicago, IL, USA).

Data were summarized using means, standard errors, numbers and percentages, as appropriate. The chi-square test was used for dichotomous variables and the independent-samples t test for continuous variables with normal distribution. Multivariate analysis was used to determine predictors of CRS and in-hospital mortality. Statistical significance was defined as $p < 0.05$.

Results

Patient characteristics

One hundred and eight consecutive patients admitted to our cardiac intensive care unit with AHF were studied. Mean age was 66 ± 15 years and 74% were male. According to the decision of the admitting physician, 77 patients (71%) were treated with levosimendan and the remaining 31 (29%) with dobutamine.

Comparison of baseline characteristics and therapeutic strategies

Patients in the levosimendan group were younger and more frequently male.

No differences were found between the groups in HF etiology (ischemic vs. non-ischemic) or previous history of coronary artery disease, hypertension, diabetes or chronic kidney disease. In both groups, the incidence of new-onset HF was similar. The most frequent precipitating factor (acute coronary syndrome: 35% vs. 55%, $p = 0.06$) was similar in both groups, as were atrial fibrillation incidence at admission and previous use of beta-blockers. Table 1 presents the details of the above data.

Table 2 summarizes the main clinical, laboratory and echocardiographic data at admission. Systolic blood pressure and hemoglobin were lower in the dobutamine group and total bilirubin was higher in the levosimendan group, but there were no differences in sodium, potassium,

Table 1 Comparison of patient characteristics at baseline.

	LvG (n=77)	DbG (n=31)	p
Age, years	64 \pm 14	73 \pm 16	<0.01
Male	81%	58%	0.02
Hypertension	65%	71%	0.55
Diabetes	29%	39%	0.31
CKD	28%	36%	0.42
History of CAD	25%	32%	0.42
Ischemic etiology of HF	49%	61%	0.26
New-onset HF	55%	52%	0.8
AF at admission	33%	23%	0.31
Previous use of beta-blockers	47%	33%	0.16

AF: atrial fibrillation; CAD: coronary artery disease; CKD: chronic kidney disease; DbG: dobutamine group; HF: heart failure; LvG: levosimendan group.

Table 2 Main clinical, laboratory and echocardiographic data.

	LvG (n=77)	DbG (n=31)	p
Systolic blood pressure, mmHg	119±32	104±31	0.04
<i>Laboratory data</i>			
Hemoglobin, g/dl	13.4±2	12.5±2	0.04
Total bilirubin, µmol/l	21±15	15±8	0.01
Sodium, mmol/l	138±4	138±5	0.71
Potassium, mmol/l	4.5±0.8	4.6±1.0	0.57
Alkaline phosphatase, U/l	106±47	162±106	0.08
AST, U/l	229±640	99±160	0.46
ALT, U/l	170±377	111±160	0.57
<i>Renal function</i>			
eGFR, ml/min/1.73 m ²	61±30	56±28	0.42
Cystatin C, mg/l	1.4±0.7	1.6±0.7	0.31
Creatinine, µmol/l	130±59	131±70	0.93
BUN, mmol/l	13±9	14±12	0.71
<i>Echocardiographic data</i>			
LVEF, %	27±9	35±12	<0.01
Diastolic dysfunction, %	89	82	0.38

ALT: alanine transaminase; AST: aspartate transaminase; BUN: blood urea nitrogen; DbG: dobutamine group; eGFR: estimated glomerular filtration rate; HF: heart failure; LVEF: left ventricular ejection fraction; LvG: levosimendan group.

alkaline phosphatase, AST or ALT. LVEF was lower in the levosimendan group, with no differences between groups regarding prevalence of diastolic dysfunction.

Table 3 shows the main differences in treatment between the groups. There were no differences in maximum daily dose of furosemide or its form of administration (bolus vs. infusion). The use of intra-aortic balloon-pump counterpulsation and urgent revascularization was similar between groups. Noradrenaline and dopamine in vasodilator doses were more frequent in the dobutamine group, as was the need for renal support therapy and mechanical ventilation.

Primary and secondary endpoints

The dobutamine group had a higher incidence of the primary endpoint of CRS (49% vs. 77%, $p<0.01$) and lower minimum eGFR (44 ± 22 vs. 31 ± 18 ml/min/1.73 m², $p<0.01$).

Furthermore, the percentage of decrease in eGFR during hospital stay was higher in the dobutamine group than in the levosimendan group ($24\pm21\%$ vs. $38\pm28\%$, $p=0.02$).

At discharge, patients who received dobutamine presented a trend towards partial recovery in renal function (eGFR 56 ± 28 ml/min/1.73 m² at admission vs. 45 ± 25 ml/min/1.73 m² at discharge, $p=0.06$), unlike patients treated with levosimendan (eGFR 61 ± 30 ml/min/1.73 m² at admission vs. 60 ± 27 ml/min/1.73 m² at discharge, $p=0.67$).

Changes in renal function parameters are represented in Figure 1.

Using logistic regression analysis, which included all variables that differed between the groups, cystatin C (odds ratio [OR] 8.6, 95% confidence interval [CI] 1.8-40.7, $p=0.007$) was identified as the only predictor for CRS development during hospital stay ($p=0.73$ for the Hosmer-Lemeshow test).

In-hospital prognosis

Length of stay was similar in both groups (10 ± 8 vs. 12 ± 9 days, $p=0.29$). In-hospital mortality (19%) was higher in the dobutamine group (9% vs. 42%, $p<0.01$). CRS (OR 13,

Table 3 Main differences in therapeutic strategies between the study groups.

	LvG (n=77)	DbG (n=31)	p
Max. daily furosemide dose, mg	147±111	55±126	0.76
IABP	5%	7%	0.8
Urgent revascularization	31%	48%	0.09
Noradrenaline	7%	28%	<0.01
Vasodilator dopamine dose	5%	38%	<0.01
Renal support therapy	1%	10%	0.04
<i>Mechanical ventilation</i>			
Invasive	29%	51%	0.02
Noninvasive	20%	35%	0.08
	9%	16%	0.29

DbG: dobutamine group; IABP: intra-aortic balloon-pump counterpulsation; LvG: levosimendan group; Max.: maximum.




Figure 1 Changes in renal function parameters during hospitalization. eGFR: estimated glomerular filtration rate.

95% CI 1.5-114.4, $p=0.02$) and the inotrope used (OR for dobutamine 5, 95% CI 1.47-19.92, $p=0.01$) were independent predictors of mortality.

Follow-up

During follow-up (481 ± 365 days), 44 patients were readmitted due to AHF and 39 died. There were no differences between the groups regarding mortality (41% vs. 56%, $p=0.28$), readmission due to AHF (47% vs. 61%, $p=0.29$), or the composite endpoint of death and readmission due to AHF (64% vs. 67%, $p=0.85$).

Discussion

Renal dysfunction is one of the most important and prevalent comorbidities of HF and has emerged as a critical risk factor for prolonged hospitalization and rehospitalization and short- and long-term mortality in patients with AHF.¹⁸ The prevalence of CRS in our study was very high in both groups (49% and 77%) (although similar to that reported in a sub-analysis of the ADHERE database⁴), and was an independent predictor of mortality, associated with a risk of death thirteen times higher than in those who did not develop CRS. The high prevalence of acute kidney injury might be explained by the characteristics of our study population, since we only included patients who required treatment with inotropes, which is a surrogate marker of low cardiac output. Factors such as age (mainly elderly) and high incidences of hypertension, diabetes and coronary artery disease, all of them recognized contributors to renal dysfunction, may also have had an impact.⁴

Unfortunately, the clinical management of CRS is largely empirical and many drugs traditionally used to treat HF (diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and aldosterone antagonists) may result in renal dysfunction due to their serious side effects, especially following inappropriate or excessive use.^{19,20}

Levosimendan is a positive inotropic drug with vasodilatory properties that has been assessed in several clinical studies in patients with AHF, which demonstrated improvements in renal hemodynamics and laboratory markers of renal function.^{13,14,21-24} However, there are few studies comparing the renoprotective profile of levosimendan with that of dobutamine in patients with AHF.^{13,14} The randomized controlled LIDO trial²¹ reported a significant reduction of 9% in creatinine level in patients with almost normal renal

function when treated with levosimendan as opposed to dobutamine. In patients with moderate renal impairment, levosimendan was found to have a more robust effect on eGFR, with an increase of 45% at 72 hours, compared with dobutamine infusion.²¹ Similarly, the nonrandomized PORTLAND study²² assessed the efficacy and safety of levosimendan in the treatment of AHF in everyday clinical practice. There was rapid improvement in diuresis in previously oliguric patients after beginning levosimendan, along with a reduction in serum creatinine levels that persisted at five days.²² Yilmaz et al.¹³ investigated 88 consecutive patients with AHF (NYHA class III-IV) who required inotropic therapy. Patients were randomized to receive either levosimendan or dobutamine. While LVEF increased significantly in both treatment groups, the levosimendan group showed significant improvement in eGFR after 24 hours (+15.3%), while the dobutamine arm showed no difference (-1.33%).¹³ The same group also compared the effects of levosimendan and dobutamine on right ventricular function in 40 consecutive patients with severe chronic biventricular dysfunction and showed that right ventricular function improved more in patients receiving levosimendan.¹⁴ Furthermore, in these patients levosimendan improved both 24-hour urine output and creatinine levels, whereas dobutamine produced only a small increase in urine output and no decrease in creatinine levels.¹⁴ The beneficial effect of levosimendan on renal function extends beyond AHF, according to two recent meta-analyses, in acute critically ill patients and in the perioperative setting, that showed a reduction in kidney injury.^{25,26}

In agreement with these findings, our study, which aims to describe a real-world AHF population, showed that, even though eGFR was similar in the two groups at admission, patients treated with levosimendan had a lower incidence of CRS (49% vs. 77%). Furthermore, renal function recovery at discharge was incomplete in individuals who received dobutamine, unlike in patients selected for levosimendan perfusion, who had a complete recovery.

The mechanisms underlying levosimendan's renoprotective effect in patients with AHF are not fully understood. Improved hemodynamics, and hence increased kidney perfusion, could play an important role.²⁴ However, in multivariate analysis, levosimendan therapy was shown to predict improved renal function independently of changes in left ventricular performance, suggesting that other factors may be responsible.²³ Different possible renoprotective mechanisms of levosimendan have been proposed: an increase in renal blood flow due to hemodynamic improvement,^{27,28} additional increases in renal perfusion via vasodilation

through KATP channel agonism,²⁹ reversal of AT-2-mediated mesangial cell contraction with a consequent increase in glomerular capillary surface area and glomerular filtration rate,²⁴ and possible anti-inflammatory properties, suggesting that it may protect against tubular injury.³⁰ However, systemic venodilation together with pulmonary vasodilation, improving right ventricular performance, is probably the main mechanism distinguishing the effect on renal function of this drug from that of dobutamine.¹³ Moreover, the formation of an active metabolite of levosimendan may account for the prolonged effect of this drug.³¹

Nevertheless, in our study some differences between the groups may preclude firm conclusions. Patients in the dobutamine group appeared to present in a more severe condition, as expressed by lower systolic blood pressure, lower hemoglobin levels and older age, and generally requiring more multi-organ support. On the other hand, lower systolic blood pressure may itself have influenced the choice of the inotrope by the admitting physician, since the hypotensive effect of levosimendan lasts longer.²¹

In recent years, cystatin C has received considerable attention as a potential alternative to serum creatinine for estimating kidney function, and has consistently proved a better risk marker than creatinine, especially in acute scenarios.³² In our study, admission cystatin C, but not creatinine or BUN, was an independent predictor of CRS during hospital stay. Identifying individuals at risk for developing CRS by assessing cystatin C could help the physician provide a more tailored therapeutic strategy, with a view to decreasing CRS incidence and hence improving this population's dire prognosis.

Although multivariate analysis showed the use of dobutamine was associated with a five-fold higher risk of in-hospital mortality, these results need to be assessed with caution, since they conflict with those obtained in large clinical trials comparing the impact of levosimendan and dobutamine on mortality.^{33,34} However, these differences may be explained by the differences in systolic blood pressure at admission, since median systolic blood pressure in the levosimendan group was over 100 mmHg. The inclusion of patients with low blood pressure in SURVIVE³⁴ and REVIVE-II³³ may have partly explained their results, since the beneficial effects of levosimendan in reducing central venous pressure and improving pulmonary congestion may be offset by a drop in blood pressure, which jeopardizes vital organ perfusion.³⁵ Furthermore, a recent analysis of 25 meta-analyses in different clinical settings consistently showed benefits for levosimendan, with lower relative risk for mortality, which supports our results.³⁶

Study limitations

Our study has several limitations. First, this was a single-center study with a relatively small sample size. A larger sample of patients from multiple centers would make the analysis more robust and objective. Second, the observational nature of the study means that the inotrope used and its doses were at the discretion of the attending physician. Furthermore, the lack of randomization created two heterogeneous populations that clearly differed in severity on admission, which precludes firm conclusions regarding

the superiority of levosimendan or dobutamine in terms of renoprotective profile. Finally, although the MDRD formula is currently the preferred method for estimating renal function,¹⁷ it should be applied when renal function is stable, which is probably not the case for many patients admitted with AHF.

Conclusions

Although the differences between groups preclude firm conclusions, levosimendan appears to have some renoprotective effect, as it was associated with a lower incidence of CRS and better recovery of renal function at discharge. This outcome, together with recent publications showing the benefit of levosimendan in renal protection, support the potential role of this drug in the prevention and treatment of CRS. Furthermore, identification of patients at increased risk of renal dysfunction by assessing cystatin C may enable selection of patients for levosimendan treatment, minimizing the incidence of CRS and its indisputably negative impact on AHF prognosis.

Ethical disclosures

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this study.

Confidentiality of data. The authors declare that they have followed the protocols of their work center on the publication of patient data.

Right to privacy and informed consent. The authors have obtained the written informed consent of the patients or subjects mentioned in the article. The corresponding author is in possession of this document.

Conflicts of interest

The authors have no conflicts of interest to declare.

References

1. Nieminen MS, Brutsaert D, Dickstein K, et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. *Eur Heart J.* 2006;27:2725–36.
2. Mebazaa A, Yilmaz MB, Levy P, et al. Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. *Eur J Heart Fail.* 2015;17:544–58.
3. Yilmaz MB, Grossini E, Silva Cardoso JC, et al. Renal effects of levosimendan: a consensus report. *Cardiovasc Drugs Ther.* 2013;27:581–90.
4. Heywood JT, Fonarow GC, Costanzo MR, et al. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. *J Card Fail.* 2007;13:422–30.

5. Pollesello P, Mebazaa A. ATP-dependent potassium channels as a key target for the treatment of myocardial and vascular dysfunction. *Curr Opin Crit Care*. 2004;10:436–41.
6. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. *Ann Intern Med*. 1999;130:461–70.
7. Caetano F, Barra S, Faustino A, et al. Cardiorenal syndrome in acute heart failure: a vicious cycle? *Rev Port Cardiol*. 2014;33:139–46.
8. Hillege HL, Nitsch D, Pfeffer M, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. *Circulation*. 2006;113:671–8.
9. Fonarow GC, Adams KF, Abraham WT, et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. *JAMA*. 2005;293:572–80.
10. Hillege HL, Girbes RJ, Kam PJ, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. *Circulation*. 2000;102:203–10.
11. Parissis JT, Farmakis D, Nieminen M. Classical inotropes and new cardiac enhancers. *Heart Fail Rev*. 2007;12:149–56.
12. Damman K, Navis G, Smilde TDJ, et al. Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. *Eur J Heart Fail*. 2007;9:872–8.
13. Yilmaz MB, Yalta K, Yontar C, et al. Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine. *Cardiovasc Drugs Ther*. 2007;21:431–5.
14. Yilmaz MB, Yontar C, Erdem A, et al. Comparative effects of levosimendan and dobutamine on right ventricular function in patients with biventricular heart failure. *Heart Vessels*. 2009;24:16–21.
15. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J*. 2016;37:2129–200.
16. Ronco C, McCullough P, Anker SD, et al. Acute Dialysis Quality Initiative (ADQI) consensus group. Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. *Eur Heart J*. 2010;31:703–11.
17. Kellum J, Lameire N, Aspelin P, et al. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. *Kidney Int Suppl*. 2012;2:1–138.
18. Hou Z-Q, Sun Z-X, Su C-Y, et al. Effect of levosimendan on estimated glomerular filtration rate in hospitalized patients with decompensated heart failure and renal dysfunction. *Cardiovasc Ther*. 2013;31:108–14.
19. House A, Haapio M, Lassus J, et al. Pharmacological management of cardiorenal syndromes. *Int J Nephrol*. 2011;2011(Type 1):630809.
20. Caetano F, Mota P, Almeida I, et al. Continuous infusion or bolus injection of loop diuretics for patients admitted for severe acute heart failure: is one strategy better than the other? *Rev Port Cardiol*. 2015;34:95–102.
21. Follath F, Cleland JGF, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. *Lancet*. 2002;360:196–202.
22. Silva-Cardoso J, Ferreira J, Oliveira-Soares A, et al. Effectiveness and safety of levosimendan in clinical practice. *Rev Port Cardiol*. 2009;28:143–54.
23. Zemljic G, Bunc M, Yazdanbakhsh AP, et al. Levosimendan improves renal function in patients with advanced chronic heart failure awaiting cardiac transplantation. *J Card Fail*. 2007;13:417–21.
24. Fedele F, Bruno N, Brasolin B, et al. Levosimendan improves renal function in acute decompensated heart failure: possible underlying mechanisms. *Eur J Heart Fail*. 2014;16:281–8.
25. Bove T, Matteazzi A, Belletti A, et al. Beneficial impact of levosimendan in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials. *Heart Lung Vessels*. 2015;7:35–46.
26. Zhao-Zhuo N, Shu-Ming W, Wen-Yu S. Perioperative levosimendan therapy is associated with a lower incidence of acute kidney injury after cardiac surgery: a meta-analysis. *J Cardiovasc Pharmacol*. 2014;63:107–12.
27. Sorsa T, Heikkinen S, Abbott MB, et al. Binding of levosimendan, a calcium sensitizer, to cardiac troponin C. *J Biol Chem*. 2001;276:9337–43.
28. Toivonen L, Viitasalo M, Sundberg S, et al. Electrophysiologic effects of a calcium sensitizer inotropic levosimendan administered intravenously in patients with normal cardiac function. *J Cardiovasc Pharmacol*. 2000;35:664–9.
29. Pataricza J, Krassói I, Höhn J, et al. Functional role of potassium channels in the vasodilating mechanism of levosimendan in porcine isolated coronary artery. *Cardiovasc Drugs Ther*. 2003;17:115–21.
30. Paraskevaidis I, Parissis JT, Kremastinos D. Anti-inflammatory and anti-apoptotic effects of levosimendan in decompensated heart failure: a novel mechanism of drug-induced improvement in contractile performance of the failing heart. *Curr Med Chem Cardiovasc Hematol Agents*. 2005;3:243–7.
31. Bergh CH, Andersson B, Dahlström U, et al. Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers. *Eur J Heart Fail*. 2010;12:404–10.
32. Almeida I, Caetano F, Barra S, et al. Estimating glomerular filtration rate in acute coronary syndromes: different equations, different mortality risk prediction. *Eur Heart J Acute Cardiovasc Care*. 2016;5:223–30.
33. Cleland JGF, Freemantle N, Coletta AP, et al. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. *Eur J Heart Fail*. 2006;8:105–10.
34. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. *JAMA*. 2007;297:1883–91.
35. Damman K, Voors AA. Levosimendan improves renal function in acute decompensated heart failure: cause and clinical application. *Cardiovasc Drugs Ther*. 2007;21:403–4.
36. Pollesello P, Parissis J, Kivikko M, et al. Levosimendan meta-analyses: is there a pattern in the effect on mortality? *Int J Cardiol*. 2016;209:77–83.